Table 3.
Parameter estimates. Final pharmacodynamic model
| Parameter | Description | Estimate (95% CI) | RSE (%) | IIV CV (%) | Shrinkage (%) |
|---|---|---|---|---|---|
| (ng/mL/h) | Zero-order production rate of IGF-I at zero GH levels (estimated) | 0.949 (0.411–1.49) | 28.9 | 117 | 15.1 |
| (ng/mL/h) | Zero-order production rate of IGF-I at endogenous GH levels for 85-kg adults with GHD (derived) | 1.97 | – | – | – |
| (ng/mL/h) | Zero-order production rate of IGF-I at endogenous GH levels for 25-kg children with GHD (derived) | 2.22 | – | – | – |
| (1/h) | First-order elimination rate of IGF-I | 0.0262 (0.0218–0.0306) | 8.6 | 17.4 | 31.3 |
| (ng/mL) | Somatropin concentration corresponding to half-maximum stimulation of IGF-I production rate | 2.13 (1.39–2.88) | 17.9 | ||
| (ng/mL/h) | Maximum increase in IGF-I production rate for adults with GHD | 15.1 (fixed) | – | 33.1 | 13.3 |
| Body weight covariate on the maximum increase in IGF-I production rate for adults with GHD | 0.46 (fixed) | – | – | – | |
| (ng/mL/h) | Maximum increase in IGF-I production rate for children with GHD | 6.48 (4.75–8.70) | 14.0 | 33.1 | 13.3 |
| Body weight covariate on the maximum increase in IGF-I production rate for children with GHD | 1.94 (1.05–2.84) | 23.5 | – | – | |
| Proportional error Trial 1 (%) | – | 14.6 | – | – | 9.4 |
| Proportional error Trial 2 (%) | – | 8.7 | – | – | 5.5 |
| Proportional error Trial 3 (%) | – | 11.4 | – | – | 12.0 |
BW body weight, CI confidence interval, CV coefficient of variation, Emax maximum increase in IGF-I production rate, EC50 GH concentration corresponding to half-maximum stimulation of IGF-I production rate, GH growth hormone, GHD growth hormone deficiency, IGF-I insulin-like growth factor-I, IIV inter-individual variability, Kendo zero-order process for endogenous growth hormone production, Kin zero order production rate of IGF-I, Kout first-order elimination rate of IGF-I, RSE relative standard error